WHO report on the public health response to dementia

WHO report on the public health response to dementia

The World Health Organization has published a “Global status report on the public health response to dementia” where it takes stock of actions driven by Member States, WHO and civil society since the adoption of the global action plan, identifies barriers to its implementation especially in light of the COVID-19 pandemic, and highlights areas where urgent, accelerated action is required.

According to WHO, “only a quarter of countries worldwide have a national policy, strategy or plan for supporting people with dementia and their families […]. . Half of these countries are in WHO’s European Region, with the remainder split between the other Regions. Yet even in Europe, many plans are expiring or have already expired, indicating a need for renewed commitment from governments.

At the same time, the number of people living with dementia is growing according to the report: WHO estimates that more than 55 million people (8.1 % of women and 5.4% of men over 65 years) are living with dementia. This number is estimated to rise to 78 million by 2030 and to 139 million by 2050.”

Asceneuron will present at the next ANA21 virtual meeting organized by the American Neurological Association on October 17-19, 2021.

Asceneuron will present at the next ANA21 virtual meeting organized by the American Neurological Association on October 17-19, 2021.

On October 17-19, 2021, the American Neurological Association will host its second interactive, virtual meeting experience.

Our Head of Translational Medicine Dr Ryan Schubert will present ASN51, an Orally Bioavailable Small-molecule O-Glcnacase Inhibitor, Has Both Immediate and Disease-modifying Benefits in Preclinical Models of Parkinson’s Disease and Epilepsy” at the poster tour session “Movement Disorders 2” on October 18, 2021 at 6:30 PM ET.

ANA2021 is considered the top meeting for academic neurologists and neuroscientists at every career stage, offering the opportunity to connect over groundbreaking research and best practices for success in the field.

Asceneuron to present at the 22nd International Conference on Alzheimer’s Drug Discovery be held online October 4-5, 2021.

Asceneuron to present at the 22nd International Conference on Alzheimer’s Drug Discovery be held online October 4-5, 2021.

The 22nd International Conference on Alzheimer’s Drug Discovery showcases the innovative approaches of Alzheimer’s Drug Discovery Foundation’s (ADDF) funded scientists and their newest results. In addition to featuring ADDF’s portfolio, the program also includes guest presentations focusing on the latest research in the Alzheimer’s disease field.

Dr Dirk beher has been invited to give a lecture on “OGA inhibitors as multimodal drugs for intracellular proteinopathies”, on October 4th at 4:45 PM CET (10:45 AM ET). This presentation is part of the session #1 “Clinical Trials and Novel Approaches for Dementia”.

The purpose for the annual ADDF conference is to accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging. Attendees will see the diverse cutting-edge approaches ADDF scientists are undertaking and have opportunities for networking and partnership discussions with academic, industry, and foundation thought leaders.

The event will be held online October 4-5, 2021 : further information and program

Posted :

Asceneuron’s unique approach to treat Alzheimer’s disease featured by our CEO Dirk Beher in series of interviews with industry leaders on the future of Alzheimer’s disease drug development.

Asceneuron’s unique approach to treat Alzheimer’s disease featured by our CEO Dirk Beher in series of interviews with industry leaders on the future of Alzheimer’s disease drug development.

In the article “Precision And Prevention Key To Future Of Alzheimer’s Treatment – A Look at Novel Approaches In The Alzheimer’s Pipeline” published by In Vivo on August 4th, 2021, William Masters gathered the recommentations of leading CEOs from early- to mid-stage biotechs to advance AD treatment.

Posted :

Asceneuron CEO Dirk Beher to speak at Alzheimer’s Association International Conference

Asceneuron CEO Dirk Beher to speak at Alzheimer’s Association International Conference

  • Presenting at The Peter Davies Memorial Symposium: The Future of Tau Based Therapies

Lausanne, SWITZERLAND and San Francisco, CA, USA, 28 July 2021 – Asceneuron SA, a clinical-stage biotech company dedicated to targeting the root cause of neurodegenerative diseases, is pleased to announce that Chief Executive Officer, Dirk Beher has been invited to present at The Peter Davies Memorial Symposium: The Future of Tau Based Therapies during the prestigious Alzheimer’s Association International Conference which takes place between the 26 – 30 July 2021 in Denver, USA and online. The talk will take place on Wednesday, 28 July at 08:00am MDT / 4:00pm CET.

Dr Dirk Beher will discuss the topic “O-GlcNAcase Inhibitors as Therapies for Tauopathies” and will provide an update on the current status of Asceneuron’s O-GlcNAcase inhibitor research and clinical pipeline.

Dirk Beher, Chief Executive Officer and Co-Founder of Asceneuron, commented:

“I am honoured to have been invited to present at the Peter Davies Memorial Symposium during the Alzheimer’s Association International Conference and I am looking forward to discussing and sharing the latest insights on O-GlcNAcase biology and its role in tau-related and other diseases of intracellular protein aggregation.”

The Alzheimer’s Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians, and the care research community to share research discoveries that will lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease.

Posted :

For further information about the conference programme click here